A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder
Background. Insufficient effectiveness and a difficult tolerability profile of antidepressant drugs for the treatment of major depressive disorder (MDD) have been reported, and polyunsaturated fatty acids (PUFAs) have been posited as reliable therapeutic alternatives. The present study investigated...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/3801235 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561627435630592 |
|---|---|
| author | Tommaso Accinni Matteo Panfili Lorenzo Tarsitani Massimo Biondi Massimo Pasquini Annalisa Maraone |
| author_facet | Tommaso Accinni Matteo Panfili Lorenzo Tarsitani Massimo Biondi Massimo Pasquini Annalisa Maraone |
| author_sort | Tommaso Accinni |
| collection | DOAJ |
| description | Background. Insufficient effectiveness and a difficult tolerability profile of antidepressant drugs for the treatment of major depressive disorder (MDD) have been reported, and polyunsaturated fatty acids (PUFAs) have been posited as reliable therapeutic alternatives. The present study investigated the efficacy of omega-3 PUFAs as monotherapy for MDD. Methods. Two well-trained reviewers independently looked at the most significant randomized clinical trials (RCTs) from the PubMed database regarding PUFAs’ employment in MDD compared to placebo; “major depressive disorder” and “omega-3 fatty acids,” or “omega-6 fatty acids,” or “polyunsaturated fatty acids (PUFA),” or “n − 3 polyunsaturated fatty acids,” or “eicosapentaenoic acid (EPA),” or “docosahexaenoic acid (DHA)” were used as the medical subject keywords. Results. Of the initial 96 potential RCTs based on titles and abstracts, 82 studies did not meet the inclusion criteria and were excluded. Six studies were excluded from the remaining 14 after full text revision. Eight RCTs met all the inclusion/exclusion criteria without reporting clear evidence of PUFAs’ effectiveness in the treatment of MDD. Conclusion. At present, there is no opportunity to recommend the use of omega-3 PUFAs monotherapy for the treatment of MDD, although their supplementation may be useful in some specific populations. |
| format | Article |
| id | doaj-art-412b9e8b56504fef83eb608a8a5ecc25 |
| institution | Kabale University |
| issn | 1742-1241 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Clinical Practice |
| spelling | doaj-art-412b9e8b56504fef83eb608a8a5ecc252025-02-03T01:24:36ZengWileyInternational Journal of Clinical Practice1742-12412022-01-01202210.1155/2022/3801235A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive DisorderTommaso Accinni0Matteo Panfili1Lorenzo Tarsitani2Massimo Biondi3Massimo Pasquini4Annalisa Maraone5Department of Human NeurosciencesDepartment of Human NeurosciencesDepartment of Human NeurosciencesDepartment of Human NeurosciencesDepartment of Human NeurosciencesDepartment of Human NeurosciencesBackground. Insufficient effectiveness and a difficult tolerability profile of antidepressant drugs for the treatment of major depressive disorder (MDD) have been reported, and polyunsaturated fatty acids (PUFAs) have been posited as reliable therapeutic alternatives. The present study investigated the efficacy of omega-3 PUFAs as monotherapy for MDD. Methods. Two well-trained reviewers independently looked at the most significant randomized clinical trials (RCTs) from the PubMed database regarding PUFAs’ employment in MDD compared to placebo; “major depressive disorder” and “omega-3 fatty acids,” or “omega-6 fatty acids,” or “polyunsaturated fatty acids (PUFA),” or “n − 3 polyunsaturated fatty acids,” or “eicosapentaenoic acid (EPA),” or “docosahexaenoic acid (DHA)” were used as the medical subject keywords. Results. Of the initial 96 potential RCTs based on titles and abstracts, 82 studies did not meet the inclusion criteria and were excluded. Six studies were excluded from the remaining 14 after full text revision. Eight RCTs met all the inclusion/exclusion criteria without reporting clear evidence of PUFAs’ effectiveness in the treatment of MDD. Conclusion. At present, there is no opportunity to recommend the use of omega-3 PUFAs monotherapy for the treatment of MDD, although their supplementation may be useful in some specific populations.http://dx.doi.org/10.1155/2022/3801235 |
| spellingShingle | Tommaso Accinni Matteo Panfili Lorenzo Tarsitani Massimo Biondi Massimo Pasquini Annalisa Maraone A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder International Journal of Clinical Practice |
| title | A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder |
| title_full | A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder |
| title_fullStr | A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder |
| title_full_unstemmed | A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder |
| title_short | A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder |
| title_sort | revision on the effectiveness of omega 3 polyunsaturated fatty acids as monotherapy in the treatment of major depressive disorder |
| url | http://dx.doi.org/10.1155/2022/3801235 |
| work_keys_str_mv | AT tommasoaccinni arevisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT matteopanfili arevisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT lorenzotarsitani arevisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT massimobiondi arevisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT massimopasquini arevisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT annalisamaraone arevisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT tommasoaccinni revisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT matteopanfili revisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT lorenzotarsitani revisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT massimobiondi revisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT massimopasquini revisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder AT annalisamaraone revisionontheeffectivenessofomega3polyunsaturatedfattyacidsasmonotherapyinthetreatmentofmajordepressivedisorder |